💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo
In the “JOINUS” program, Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo have established compound libraries of compounds that have been discontinued after clinical trials or preclinical studies.
We will provide this as a drug repositioning compound library to the domestic research institution that applied for this program and evaluate it using in vitro * 1 evaluation system.
In general, drug repositioning is aimed at finding different adaptation from the beginning with the concept of reusing medicine, and compounds to be treated are diverse, including approved drugs and discontinued products.
We aim at development as a new drug for compounds that did not reach the launch in the “JOINUS” program.
News Releases – Daiichi Sankyo Co., Ltd.
http://www.daiichisankyo.co.jp/news/detail/006735.html
http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006736.html